Editorial

Avastin: more questions than answers. . .

Restricted access

If the inline PDF is not rendering correctly, you can download the PDF file here.

Article Information

Please include this information when citing this paper: published online October 28, 2011; DOI: 10.3171/2011.8.JNS111107.

© AANS, except where prohibited by US copyright law.

Headings

Figures

  • View in gallery

    Recommended timing of bevacizumab treatment relative to craniotomy.

References

  • 1

    Ali SAMcHayleh WMAhmad ASehgal RBraffet MRahman M: Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases. J Neurosurg 109:2682722008

    • Search Google Scholar
    • Export Citation
  • 2

    Ballman KVBuckner JCBrown PDGiannini CFlynn PJLaPlant BR: The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol 9:29382007

    • Search Google Scholar
    • Export Citation
  • 3

    Batchelor TTSorensen AGdi Tomaso EZhang WTDuda DGCohen KS: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83952007

    • Search Google Scholar
    • Export Citation
  • 4

    Berger ACFeldman ALGnant MFKruger EASim BKHewitt S: The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing. J Surg Res 91:26312000

    • Search Google Scholar
    • Export Citation
  • 5

    Bloch WHuggel KSasaki TGrose RBugnon PAddicks K: The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing. FASEB J 14:237323762000

    • Search Google Scholar
    • Export Citation
  • 6

    Brandes AATosoni AAmistà PNicolardi LGrosso DBerti F: How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology 63:128112842004

    • Search Google Scholar
    • Export Citation
  • 7

    Brandes AATosoni ABasso UReni MValduga FMonfardini S: Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol 22:477947862004

    • Search Google Scholar
    • Export Citation
  • 8

    Chamberlain MC: Bevacizumab plus irinotecan in recurrent glioblastoma. J Clin Oncol 26:101210132008

  • 9

    Chamberlain MC: Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. J Neurooncol 56:1831882002

  • 10

    Cloughesy TVredenburgh JJDay BDas AFriedman HS: Update safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study. J Clin Oncol 28:15s2010. (Abstract)

    • Search Google Scholar
    • Export Citation
  • 11

    Cloughesy TFFilka EKuhn JNelson GKabbinavar FFriedman H: Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer 97:9 Suppl238123862003

    • Search Google Scholar
    • Export Citation
  • 12

    D'Angelica MKornprat PGonen MChung KYJarnagin WRDeMatteo RP: Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann Surg Oncol 14:7597652007

    • Search Google Scholar
    • Export Citation
  • 13

    Desjardins AReardon DACoan AMarcello JHerndon JE JrBailey L: Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer [epub ahead of print]2011

    • Search Google Scholar
    • Export Citation
  • 14

    Ellis LMCurley SAGrothey A: Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol 23:485348552005

    • Search Google Scholar
    • Export Citation
  • 15

    Erinjeri JPFong AJKemeny NEBrown KTGetrajdman GISolomon SB: Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement. Cancer 117:129613012011

    • Search Google Scholar
    • Export Citation
  • 16

    Friedman HSPrados MDWen PYMikkelsen TSchiff DAbrey LE: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:473347402009

    • Search Google Scholar
    • Export Citation
  • 17

    Fuks ZKolesnick R: Engaging the vascular component of the tumor response. Cancer Cell 8:89912005

  • 18

    Gilbert MRWang MAldape KSorensen AGMikkelson TBokstein F: RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan (CPT) or dose-dense temozolomide (TMZ) in recurrent glioblastoma (GBM). Proc Soc Neuro Oncol 12:iv392010. (Abstract)

    • Search Google Scholar
    • Export Citation
  • 19

    Glusker PRecht LLane B: Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 354:9809822006

  • 20

    Gordon MSMargolin KTalpaz MSledge GW JrHolmgren EBenjamin R: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:8438502001

    • Search Google Scholar
    • Export Citation
  • 21

    Hasselbalch BLassen UHansen SHolmberg MSørensen MKosteljanetz M: Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol 12:5085162010

    • Search Google Scholar
    • Export Citation
  • 22

    Hofer SElandt KGreil RHottinger AFHuber ULemke D: Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta Oncol 50:6306352011

    • Search Google Scholar
    • Export Citation
  • 23

    Howdieshell TRCallaway DWebb WLGaines MDProcter CD JrSathyanarayana : Antibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formation. J Surg Res 96:1731822001

    • Search Google Scholar
    • Export Citation
  • 24

    Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58622005

  • 25

    Kesmodel SBEllis LMLin EChang GJAbdalla EKKopetz S: Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 26:525452602008

    • Search Google Scholar
    • Export Citation
  • 26

    Klein SABond SJGupta SCYacoub OAAnderson GL: Angiogenesis inhibitor TNP-470 inhibits murine cutaneous wound healing. J Surg Res 82:2682741999

    • Search Google Scholar
    • Export Citation
  • 27

    Kreisl TNKim LMoore KDuic PRoyce CStroud I: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:7407452009

    • Search Google Scholar
    • Export Citation
  • 28

    Lai ATran ANghiemphu PLPope WBSolis OESelch M: Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 29:1421482011

    • Search Google Scholar
    • Export Citation
  • 29

    Lamborn KRYung WKChang SMWen PYCloughesy TFDeAngelis LM: Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 10:1621702008

    • Search Google Scholar
    • Export Citation
  • 30

    Lange-Asschenfeldt BVelasco PStreit MHawighorst TPike SETosato G: The angiogenesis inhibitor vasostatin does not impair wound healing at tumor-inhibiting doses. J Invest Dermatol 117:103610412001

    • Search Google Scholar
    • Export Citation
  • 31

    Lou ETurner SSumrall AReardon DADesjardins APeters KB: Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma. J Clin Oncol [epub ahead of print]2011

    • Search Google Scholar
    • Export Citation
  • 32

    Macdonald DRCascino TLSchold SC JrCairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:127712801990

    • Search Google Scholar
    • Export Citation
  • 33

    Moeller BJDreher MRRabbani ZNSchroeder TCao YLi CY: Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 8:991102005

    • Search Google Scholar
    • Export Citation
  • 34

    Narayana AGruber DKunnakkat SGolfinos JGParker ERaza S: A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. Clinical article. J Neurosurg [epub ahead of print October 28 2011. DOI: 10.3171/2011.9.JNS11656]

    • Search Google Scholar
    • Export Citation
  • 35

    Narayana ARaza SGolfinos JGJohnson GKnopp EAZagzag D: Bevacizumab therapy in recurrent high grade glioma: impact on local control and survival. J Clin Oncol 26:130002008. (Abstract)

    • Search Google Scholar
    • Export Citation
  • 36

    Nghiemphu PLLiu WLee YThan TGraham CLai A: Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 72:121712222009

    • Search Google Scholar
    • Export Citation
  • 37

    Norden ADYoung GSSetayesh KMuzikansky AKlufas RRoss GL: Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70:7797872008

    • Search Google Scholar
    • Export Citation
  • 38

    Prados MDLamborn KYung WKJaeckle KRobins HIMehta M: A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol 8:1891932006

    • Search Google Scholar
    • Export Citation
  • 39

    Raizer JJGrimm SChamberlain MCNicholas MKChandler JPMuro K: A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer 116:529753052010

    • Search Google Scholar
    • Export Citation
  • 40

    Reardon DADesjardins APeters KGururangan SSampson JRich JN: Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. J Neurooncol 103:3713792011

    • Search Google Scholar
    • Export Citation
  • 41

    Reardon DADesjardins APeters KBVredenburgh JJGururangan SSampson JH: Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer [epub ahead of print]2011

    • Search Google Scholar
    • Export Citation
  • 42

    Reardon DADesjardins AVredenburgh JJGururangan SSampson JHSathornsumetee S: Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer 101:198619942009

    • Search Google Scholar
    • Export Citation
  • 43

    Reddy SKMorse MAHurwitz HIBendell JCGan TJHill SE: Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 206:961062008

    • Search Google Scholar
    • Export Citation
  • 44

    Roman CDChoy HNanney LRiordan CParman KJohnson D: Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats. J Surg Res 105:43472002

    • Search Google Scholar
    • Export Citation
  • 45

    Sathornsumetee SDesjardins AVredenburgh JJMcLendon REMarcello JHerndon JE: Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol 12:130013102010

    • Search Google Scholar
    • Export Citation
  • 46

    Scappaticci FAFehrenbacher LCartwright THainsworth JDHeim WBerlin J: Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91:1731802005

    • Search Google Scholar
    • Export Citation
  • 47

    Semenza GL: Intratumoral hypoxia, radiation resistance, and HIF-1. Cancer Cell 5:4054062004

  • 48

    Stark-Vance V: Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro Oncol 7:3422005. (Abstract)

  • 49

    Streit MVelasco PRiccardi LSpencer LBrown LFJanes L: Thrombospondin-1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice. EMBO J 19:327232822000

    • Search Google Scholar
    • Export Citation
  • 50

    Stupp RMason WPvan den Bent MJWeller MFisher BTaphoorn MJ: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:9879962005

    • Search Google Scholar
    • Export Citation
  • 51

    Tanaka HTaniguchi HMugitani TKoishi YMasuyama MKoyama H: Angiogenesis inhibitor TNP-470 prevents implanted liver metastases after partial hepatectomy in an experimental model without impairing wound healing. Br J Surg 83:144414471996

    • Search Google Scholar
    • Export Citation
  • 52

    Vredenburgh JJDesjardins AHerndon JE JrMarcello JReardon DAQuinn JA: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:472247292007

    • Search Google Scholar
    • Export Citation
  • 53

    Vredenburgh JJDesjardins AReardon DAPeters KBHerndon JE JrMarcello J: The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res 17:411941242011

    • Search Google Scholar
    • Export Citation
  • 54

    Wachsberger PRBurd RCardi CThakur MDaskalakis CHolash J: VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int J Radiat Oncol Biol Phys 67:152615372007

    • Search Google Scholar
    • Export Citation
  • 55

    Wen PYMacdonald DRReardon DACloughesy TFSorensen AGGalanis E: Updated response assessment criteria for high-grade gliomas: response assessment in neurooncology working group. J Clin Oncol 28:196319722010

    • Search Google Scholar
    • Export Citation
  • 56

    Wong ETGautam SMalchow CLun MPan EBrem S: Bevacizumab for recurrent glioblastoma multiforme: a metaanalysis. J Natl Compr Canc Netw 9:4034072011

    • Search Google Scholar
    • Export Citation
  • 57

    Wong ETHess KRGleason MJJaeckle KAKyritsis APPrados MD: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:257225781999

    • Search Google Scholar
    • Export Citation
  • 58

    Yung WKAlbright REOlson JFredericks RFink KPrados MD: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:5885932000

    • Search Google Scholar
    • Export Citation
  • 59

    Zhang FLei MPOswald TMPang YBlain BCai ZW: The effect of vascular endothelial growth factor on the healing of ischaemic skin wounds. Br J Plast Surg 56:3343412003

    • Search Google Scholar
    • Export Citation
  • 60

    Zuniga RMTorcuator RJain RAnderson JDoyle TEllika S: Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 91:3293362009

    • Search Google Scholar
    • Export Citation
  • 61

    Zustovich FLombardi GPastorelli DFarina PFurini LManara R: Bevacizumab and glioblastomas, a single-centre experience: how disease history and characteristics may affect clinical outcome. Anticancer Res 30:521352162010

    • Search Google Scholar
    • Export Citation
  • 1

    Gerstner ERChen PJWen PYJain RKBatchelor TTSorensen G: Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro Oncol 12:4664722010

    • Search Google Scholar
    • Export Citation
  • 2

    Gutin PHIwamoto FMBeal KMohile NAKarimi SHou BL: Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 75:1561632009

    • Search Google Scholar
    • Export Citation
  • 3

    Jain Rdi Tomaso EDuda DLoeffler JSorensen ABatchelor T: Angiogenesis in brain tumours. Nat Rev Neurosci 8:6106222007

  • 4

    Lai ATran ANghiemphu PLPope WBSolis OESelch M: Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 29:1421482011

    • Search Google Scholar
    • Export Citation
  • 5

    Sathornsumetee SCao YMarcello JEHerndon JE JrMcLendon REDesjardins A: Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 26:2712782008

    • Search Google Scholar
    • Export Citation
  • 6

    Sawlani RNRaizer JHorowitz SWShin WGrimm SAChandler JP: Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging—pilot study. Radiology 255:6226282010

    • Search Google Scholar
    • Export Citation
  • 7

    Stupp RHegi MENeyns BGoldbrunner RSchlegel UClement PM: Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 28:271227182010

    • Search Google Scholar
    • Export Citation
  • 8

    Vredenburgh JJDesjardins AKirkpatrick JPReardon DAPeters KBHerndon JE Jr: Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys [epub ahead of print]2010

    • Search Google Scholar
    • Export Citation

TrendMD

Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 86 86 3
Full Text Views 70 70 0
PDF Downloads 102 102 0
EPUB Downloads 0 0 0

PubMed

Google Scholar